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Does the number of doses matter? A qualitative study of HPV vaccination acceptability 1 
nested in a dose reduction trial in Tanzania. 2 
 3 
ABSTRACT (198) 4 
Background: The multi-dose regimen is a known barrier to successful human papillomavirus 5 
(HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against 6 
HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage 7 
in low and middle income countries (LMICs) are poorly understood. We investigated 8 
acceptability of dose-reduction among girls, and parents/guardians of girls, randomised to 9 
receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study 10 
(DoRIS trial) in Tanzania. 11 
Methods: Semi-structured interviews with girls (n=19), and parents/guardians of girls (n=18), 12 
enrolled in the study and completing their vaccine course.   13 
Results: Most participants said they entrusted decisions about the number of HPV vaccine 14 
doses to ‘experts’. Random allocation to the different dose groups did not feature highly in the 15 
decision to participate in the trial. Given a hypothetical choice, girls generally said they would 16 
prefer fewer doses in order to avoid the pain of injections. Parental views were mixed, with most 17 
wanting whichever dose was most efficacious. Nonetheless, parents sometimes equated a 18 
higher number of doses with greater protection. 19 
Conclusion: Vaccine trials and programmes will need to employ careful messaging to explain 20 
that one dose offers sufficient protection against HPV should emerging evidence from ongoing 21 
dose-reduction clinical trials support this. 22 
Clinical trial registration: NCT02834637 23 
 24 












1. INTRODUCTION 27 
  28 
 Persistent human papillomavirus (HPV) infection, a pre-requisite for development of 29 
cervical cancer, can be prevented by three highly efficacious licensed vaccines that protect 30 
against infection with a number of high-risk HPV genotypes [1].  The vaccine is usually 31 
targeted to girls prior to sexual debut and is currently administered in two or three dose 32 
schedules. As of May 2020, 127 countries across the world had introduced HPV 33 
vaccination programmes, but only 22 (17.3%) of these were among low-and-middle-income 34 
countries (LMIC) [2]. There are stark global disparities, such that populations with the 35 
highest incidence of HPV infection and cervical cancer mortality are least likely to be 36 
protected by vaccination. By 2014, only 1% of women targeted by immunisation 37 
programmes globally were from low income countries [3].  38 
 39 
 Worldwide by 2014, 50.1% of the target population (typically girls between 9-15 years) had 40 
received one vaccination but only 39.7% had received the full course (minimum of two 41 
doses) [3, 4]. Evidence from high income countries suggests that non-completion of the 42 
allocated dosing schedule is linked both to poverty and ethnicity, alongside other factors [5].  43 
Number of doses is rarely investigated in studies of vaccine acceptability in low-income 44 
settings. However, in a small Kenyan study of women attending family planning services, 45 
more mothers said that they would be willing to have their daughters vaccinated with HPV 46 
vaccine if one injection was required (86%) compared with three (31%) [6].  Such 47 
preferences appeared underpinned by concerns about cost to families, an important barrier 48 
to acceptability in Sub-Saharan Africa [7]. A review of delivery strategies in LMIC concluded 49 
that non-vaccination and non-completion were driven more by programmatic factors, 50 
including lack of awareness and school absenteeism, than by opposition to the vaccine 51 











highlighted the challenge of reaching girls with three doses of the vaccine where school 53 
attendance is very low [9].  54 
 55 
 A number of resource-poor countries have been hesitant in scaling-up HPV vaccination 56 
programmes, citing concerns about the sustainability of offering a multi-dose vaccine 57 
schedule to pre-adolescent and adolescent girls [10]. Feasibility of vaccine delivery is a key 58 
determinant of vaccine acceptability at national level [11] and the three-dose regimen is a 59 
known barrier to successful vaccination [12].  A reduction in the number of doses required 60 
is considered crucial to efforts to increase coverage in low income settings [3].  A single 61 
dose vaccination schedule would increase compliance, simplify delivery and allow 62 
considerable savings in terms of vaccines, consumables, disposal, outreach visit costs and 63 
staff time away from health facilities [13]. 64 
 65 
 There is emerging biological evidence from studies conducted in Costa Rica [14] and India 66 
[15] that one dose could protect against HPV infection. If immune responses, efficacy and 67 
safety are confirmed to be similar following one dose compared to multi-dose schedules, 68 
adoption of a single dose regimen is likely to be rapid, particularly in resource-poor settings.  69 
Although the case for a single dose seems robust in terms of cost and accessibility, it 70 
cannot be simply assumed that one dose will be more acceptable to parents/guardians and 71 
their daughters. In Sub-Saharan Africa, vaccine uptake has tended to be high even where 72 
knowledge is low [7], but information is lacking on beliefs about dosage and whether these 73 
might have a bearing on vaccine acceptability. Prior to country programmes administering 74 
single-dose HPV vaccination, such questions are hypothetical, but they can be explored in 75 












 We report views on dosage from a qualitative acceptability study conducted during the 78 
second year of an HPV vaccine trial (A Dose Reduction Immunobridging and Safety Study 79 
of two HPV vaccines in Tanzanian girls (DoRIS; clinicaltrials.gov: NCT02834637)) taking 80 
place in Mwanza, Tanzania [16].  81 
 82 
2. METHODS 83 
 84 
2.1 Brief introduction to the parent trial 85 
 DoRIS is an unblinded, randomised trial whose main objectives are to compare the 86 
immunogenicity and safety of one, two and three doses of two different HPV vaccines in 9-87 
14 year old Tanzanian girls [16, 17]. After taking informed consent from parents/guardians 88 
and informed assent from potential participants, the trial enrolled 930 girls and randomly 89 
assigned them to one of 6 arms (155 girls per arm). Each arm received either the 2-valent 90 
(Cervarix®) or 9-valent (Gardasil-9®) vaccine, given as either one, two, or three dose 91 
schedules. Participants are being followed up for up to 60 months following the first dose. 92 
Blood is taken at specific follow-up visits for immunogenicity measurements, malaria testing 93 
and for antibodies to herpes simplex type 2 (HSV-2), a marker of sexual behaviour.  94 
 This paper presents findings of a nested qualitative study which aimed to understand 95 
attitudes of trial participants towards vaccine dosage and the HPV vaccine in general. Here 96 
we focus on objective one: to explore views on vaccine dosage amongst trial participants 97 
and their parent/guardians, and whether these views have a bearing on acceptability of the 98 
vaccine. 99 
 100 
2.2 Acceptability study design 101 
 We conducted semi-structured interviews with: i) girls aged 9 to 14 (n=13), (ii) parents of 102 











Originally the study planned to include interviews with individuals who did not complete their 104 
assigned vaccine schedule but remained in the trial. However, no eligible non-completers 105 
were identified in the trial (five girls (0.5%) missed one or two vaccine doses but left the 106 
study (e.g. due to relocation or concerns about vaccine safety); two girls (0.2%) missed 107 
their month 6 visit but were in the single dose arm and so did not miss a dose). Data for this 108 
qualitative study were collected between January and December 2018. 109 
 110 
2.2.1 Sampling 111 
 Girls who had completed their allocated vaccination course and attended their clinic visit 112 
scheduled for six months after the first vaccine dose, were eligible for selection.  Girls were 113 
stratified by trial arm and age (9-11 or 12-14 years), and then selected for inclusion in the 114 
qualitative study using simple random sampling within strata. Random selection was done 115 
by the trial data manager using a computer randomization algorithm. In each arm, 15 116 
participants were selected (two back-up participants per interviewee in case of refusal). 117 
This list of 90 girls was then viewed by the research team to check for reasonable variation 118 
by religion, tribe, rural versus urban location, and primary versus secondary school.  119 
Parent/guardian interviewees were identified via daughters on this list. 120 
 121 
2.2.2 Participant recruitment 122 
 DoRIS trial staff members made initial contact with selected participants to introduce the 123 
qualitative study and to inform them that a member of the qualitative study team would be in 124 
touch with them. A female qualitative researcher followed up with each girl’s 125 
parent/guardian to invite them to a brief introductory meeting to explain the study. This was 126 
held at a place convenient to participants (usually home; sometimes place of work). The 127 
researcher explained the study, indicated whether a girl, parent or paired interview was 128 










date and place was scheduled a few days later with those expressing willingness to 130 
participate. If a parent or daughter declined to participate, a replacement was selected from 131 
the same stratum (this occurred only once). Parents provided written informed consent for 132 
themselves and on behalf of their daughters, depending on interview type. Illiterate parents 133 
provided witnessed consent by thumb print. Girls provided written assent prior to interview. 134 
Depending on participants’ preferences, interviews were conducted at their home or at the 135 
study clinic. Choice of venue was based on convenience and need for privacy and quiet.   136 
 137 
2.2.3 Interview topic guide 138 
 The interviews probed for existing knowledge of the HPV vaccine and cancer; experience of 139 
getting the HPV vaccine (e.g. pain, side-effects; daughter’s experience if parent was 140 
interviewed), views on vaccine dosage; and how the decision was made to take part in the 141 
DoRIS trial. The paired interviews explored parent-child dynamics as well as individual 142 
perspectives.  143 
  144 
 To facilitate discussion, participants were also presented with a set of cards, each 145 
describing a different factor that they may or may not have considered in deciding whether 146 
to participate in the trial. They were asked to sort the cards into three piles which reflected 147 
whether they had ‘thought about this a lot’, ‘thought about this a little or ‘did not consider 148 
this’. In paired interviews, parents and daughters sorted the cards together, with discussion. 149 
The cards included the following factors: severity of cervical cancer; risk of getting cervical 150 
cancer if not vaccinated; how effective the vaccine is; own age/daughters age; how safe the 151 
vaccine is; side-effects such as pain/fever; the fact that the vaccine protects against a 152 
disease that is sexually transmitted; and dosage. The card exercise was abandoned for 153 













2.2.4 Analysis 157 
 All interviews were audio recorded with permission, transcribed verbatim into Swahili and 158 
then translated into English. Transcripts were checked for clarity and quality before and 159 
after translation. Data were analysed thematically following the Framework approach 160 
(Ritchie & Lewis, 2003)[18]. The analysis team (KM, TE and GM) first familiarized 161 
themselves with the data by reading through the English transcripts. An initial thematic 162 
coding frame was developed based on the study aims and initial reading of data. The 163 
coding frame was refined through reading of transcripts and discussion between analysts. 164 
All transcripts were read and coded by TE and GM in QSR NVivo 11 [19] using the final 165 
coding frame. The process was iterative and involved regular discussion between analysts, 166 
and going back and forth between data and interpretation.  As a reliability check, a third of 167 
randomly selected transcripts were double coded and, via discussion, consistency across 168 
coders was deemed reasonable.   169 
 170 
 The card exercise served both as a discussion prompt and a means of ranking key factors 171 
based on how much they were considered in the decision to participate in the trial. Given 172 
the qualitative nature of the sample, these counts were simply intended to support and 173 
validate the qualitative insights   174 
 175 
2.3 Ethical approval 176 
 177 
 The study was approved by the National Health Research Ethics Committee (NatHREC) in 178 
Tanzania (ref: NIMR/HQ/R.8a/Vol.IX/2682) and the Ethics Committee of the London School 179 












3. RESULTS 182 
 183 
3.1 Participants 184 
 The qualitative study participants were daughters and/or parents/guardians who had 185 
assented/consented to participate in the DoRIS trial and had completed their assigned 186 
vaccination schedule.  187 
 188 
 We conducted individual interviews with 13 girls and 12 (different) parents, plus interviews 189 
with 6 (different)  girls together with their  parent/guardian. All participants lived in the trial 190 
study location of Mwanza, a large city on the south-east edge of Lake Victoria. The sample 191 
was predominantly urban, Christian and educated to primary level (Table 1). 192 
 193 
[Table 1 here] 194 
 195 
3.2 Extent to which randomisation by dosage was considered in the decision to 196 
participate in the trial 197 
 All DoRIS trial participants were informed at the trial recruitment stage that they would be 198 
randomized to receive one, two or three vaccine doses. Among the participants in this 199 
qualitative study (all of whom had ultimately opted to participate in the trial), dosage did not 200 
appear to feature highly in their decision to participate.  201 
 202 
 As part of the interview, older girls (12-14 years), parents/guardians and parent/guardian-203 
daughter dyads were asked to sort a set of cards listing potential considerations according 204 
to whether they thought about them a lot, a little or not at all (see methods and table 2) 205 











think most about the consequences of getting cervical cancer, the risk of getting the 207 
disease if unvaccinated and the effectiveness of the vaccine:  208 
 "Because I heard that when you get cervical cancer, it can lead you to death…   and when I 209 
heard that there is a cancer vaccine […] I decided to take part." (Girl aged 13 years; 1 dose 210 
arm).   211 
 212 
 Appreciation of the severity of cervical cancer was sometimes based on personal 213 
experience:  214 
 "because I have come across several cases…like two of them, people who suffered from 215 
cervical cancer, so when I saw that there is this vaccine and it can help…[…] I saw it was 216 
good for [my daughter] to participate...... “(Mother aged 45-50 years; 3 dose arm)   217 
 218 
 The next most common considerations were girl’s age, vaccine safety, side-effects and the 219 
fact that the vaccine protected against an STI. It was notable that all the girls said they 220 
considered side-effects such as pain and fever, but half the parents said they did not 221 
consider this. While three-quarters of the parents thought a lot about whether their daughter 222 
was at an appropriate age for vaccination, only a third of girls did so (though note that small 223 
numbers mean these observations are only indicative). 224 
 225 
 Other considerations, particularly for parents, involved the cost of treating cervical cancer:  226 
 “the first [consideration] was that I am poor. Because of poverty I will not be able to treat my 227 
child if she gets that disease because it is expensive to treat; what can I do? So I accepted 228 
[to join the trial].” (Mother aged 45-50 years; 2 dose arm).  229 
 230 










 "Even if I get ill, Dad simply calls them (research team) and I get fetched (by the 232 
researchers)." (Girl aged 12 years; 3 dose arm) 233 
 234 
[Table 2 here] 235 
 236 
3.3 Entrusting the dosage question to ‘experts’ 237 
 Parents tended to frame the ultimate decision to participate in the trial as a matter of placing 238 
trust in the scientists and researchers. This trust in expertise in some ways simplified the 239 
decision to participate as it positioned key aspects of the trial – including dosage – as 240 
outside of their concern:   241 
 "....about the number of doses, I did not consider that at all…because you (researchers) are 242 
the ones who know about [that]. I really don’t know anything about [it], so I leave that to you 243 
guys to decide…If you tell me that within a year there is this number of doses, then it's 244 
okay… because I was the one who decided to take part […] We did not think at all about 245 
how many doses she would receive […] If you tell us 3 vaccine doses, or 2 or 1, that’s ok." 246 
(Mother aged 45-50 years; 3 dose arm)  247 
 248 
 For the same reason, dosage did not appear to be a factor affecting the acceptability of the 249 
trial. For instance, the parent below was at pains to establish their lack of expertise while 250 
simultaneously demonstrating this lack through their misunderstanding of the vaccine as 251 
‘treatment’: 252 
 "…..… I am not the expert and the ones responsible for treating her are the experts who 253 
have studied this vaccine. So I may demand for her to be vaccinated with four doses which 254 
in turn may later be harmful yet the two doses could be enough to treat, so I cannot explain 255 












 This trust in experts with respect to dosage was illustrative of a broader trust, and even 258 
‘faith’, in scientific research among those who had opted to participate in the trial:  259 
 260 
 "My trust is through the seminars we received from the experts… because I am not an 261 
expert, I just agree with what I am told by them, as I said before I am doing this by faith […] 262 
they said it is a successful vaccine so I also trust it is going to be effective in her life." 263 
(Mother aged 35-40 years; 1 dose arm)  264 
 265 
 There was also a broader trust in government vaccination programmes, again sometimes 266 
borne of personal experience:  267 
 "[...] when I was growing up, so many people were dying of smallpox and a lot of children 268 
died due to measles but […] now even measles […] does [not] kill a lot of children and I can 269 
see that even smallpox has vanished...so that was something that was […] motivating me a 270 
lot..." (Mother aged 50-55 years; 3 dose arm).   271 
 272 
3.4 Trust and mistrust: the context of decision-making 273 
 The trust exhibited by those who had opted to join the trial may have reflected the typically 274 
polarised context in which the decision was made. Those attending the trial sensitisation 275 
meetings were often required to weigh up information given by the trial implementers 276 
against opposition and rumours about vaccine trials circulating among neighbours and 277 
community members.    278 
 279 
 "… people were saying that white people intend to destroy our kids. Many parents had this 280 
same view; they’d asked the doctors about it but the doctors said it wasn’t true and 281 
explained further. So some of them believed what doctors said but others quit [decided not 282 












 These rumours were perceived as fear-inducing. They included that the vaccine would plant 285 
a bacteria in the body, sterilise their children or take away their virginity, and that 286 
vaccinations were part of a terrorist plot. Parents sometimes encountered these views 287 
immediately, on the walk home from sensitisation meetings: 288 
 "[after the] parents meeting at school, we were returning home in groups […], they 289 
(neighbours/friends) asked us where we were coming from. We told them that we were 290 
called for cervical cancer vaccine meeting. Others said, 'those things are nonsense. You 291 
are going to be planted with bacteria which will bring you problems in the future'." Mother 292 
aged 40-45 years; 1 dose arm).  293 
 294 
 The decision to participate was complex and involved balancing benefit against risks that 295 
were difficult to assess without expert knowledge and training. Not having this knowledge 296 
themselves, community members ultimately had to decide whether to trust what they were 297 
told by the ‘doctors’ (trial implementers or other health professionals), draw on their own 298 
experience and knowledge, or listen to the beliefs circulating among the community. 299 
Participants described how they actively sought out advice from people they trusted, 300 
including family members and health professionals: 301 
 "I went to consult that doctor (a friend). I told her that our children have been called at 302 
school for this [vaccine trial] and parents had also been informed. She told me that is fine, 303 
there is no problem....so I became certain after talking to that doctor and I got peace." 304 
(Mother aged 40-45 years; 1 dose arm). 305 
 306 
 The sensitisation meetings and work by the trial team to explain the trial were fundamental 307 











 "… but when they came and educated us and gave us the forms, we read and understood 309 
that this vaccine is very important and that is how I was courageous enough to let my 310 
daughter take part in the vaccination” (Mother aged 50-55 years; 2 dose arm)   311 
 312 
 The parent above perceived the decision as one requiring courage. Fear of vaccination 313 
among community members and hesitancy about taking part, is illustrated in this account of 314 
parents changing their mind about participation after seeing that girls who were vaccinated 315 
were fine:   316 
 "...so later when they (parents who had previously refused to join the trial) saw that my 317 
daughter was doing well, they decided to […] ask […] me. I informed them that there were 318 
no more chances left." (Mother aged 45-50 years; 3 dose arm)  319 
 320 
 Against this backdrop of fear and hesitancy and having ultimately opted to put their faith in 321 
the scientists, the trust displayed by those taking part appeared to extend to all aspects of 322 
the trial, including the decisions around dose.  323 
 324 
3.5 Hypothetical preferences for one, two or three doses 325 
 Both parents and daughters were asked whether, given a choice, they would prefer one, 326 
two or three doses of the vaccine.  Some (particularly the girls) found this hypothetical 327 
question difficult; they were able to state a preference but not always able to give a reason. 328 
Some found it difficult to think of advantages of one dose schedule over another. Others, 329 
particularly parents, were reluctant to give an opinion, believing that it was a matter of 330 
scientific research. A few girls were confused between dosage and trial randomisation arm, 331 
assuming that arm A must be the ‘best’ since A is associated with a top grade at school. 332 
Several parents misunderstood or forgot the randomisation by dosage, believing allocation 333 











on dosage, four considerations emerged: avoidance of pain, societal benefit, cost saving, 335 
and efficacy.   336 
 337 
 Pain avoidance. Almost all of the girls said they would prefer one dose of the vaccine, 338 
rather than two or three. This was primarily due to fear of the injection and a desire to avoid 339 
the pain it caused:  340 
 ‘I love the vaccination but I am afraid […] I feel like the syringe is too long and I can’t 341 
imagine that all of it enters my body’ (Girl aged 10 years; 2 dose arm).  342 
 343 
 Most girls expressing a preference to avoid pain did so on the understanding that one dose 344 
was just as likely to be efficacious as two or three. However, for some girls fear of the 345 
injection over-rode any concerns about which number of doses was most effective; they 346 
would prefer one dose regardless. Girls in the one dose arms reported feeling ‘lucky’ and 347 
happy with their group since they had received fewer injections than girls in other arms. A 348 
few girls who had received three doses reported negative reactions from those receiving 349 
one or two doses, although this did not deter them from participation: 350 
 “From the whole group, I was the only one who was given 3 doses, they (other students) 351 
asked me, 'you mean they are injecting you three times?!… We are being injected only 352 
once. It is better if you just quit'[…] I just ignored them”, (Girl aged 14  years (paired 353 
interview); 3 dose arm).  354 
 355 
 Societal benefit: Four parents expressed a preference for one dose on the basis that one 356 
dose per child would mean the vaccine could be distributed among far more children for the 357 
same cost:  358 
"Well, I would wish that my daughter would have been given one vaccine dose so that 359 











received two vaccine doses, then two children would have been vaccinated” (Mother aged 361 
50-55 years; 3 dose arm).    362 
 363 
 Reduced cost: A few parents also raised the point that outside of the trial context, one dose 364 
would imply less personal cost. In addition to payment for the vaccine itself, they mentioned 365 
the cost of travelling to a clinic and potential lost earnings involved in accompanying 366 
children. Asked why they thought the scientists might be investigating whether one dose 367 
could be effective, one parent thought it could be about broader cost savings: 368 
 “Perhaps, they (researchers) have seen that one vaccine dose has the same protection and 369 
that is why they see a possibility of reducing [it]. They [the trial scientists] mentioned that 370 
these vaccine doses are very expensive, so probably to also reduce cost”. (Mother aged 371 
35-40 years; 1 dose arm).   372 
 373 
 Conversely, in the context of the vaccine trial, three doses were seen as beneficial by 374 
some, because they implied more clinical attention to their daughter and this was viewed as 375 
a benefit: 376 
 "I really wished [my daughter] had received three vaccine doses. […] Yes, there is an extra 377 
thing (in three doses) because they have researched on her more. (Mother aged 45-50 378 
years; 2 dose arm).  379 
 380 
 Efficacy: Most parents recalled that the trial sought to establish whether different numbers 381 
of doses might be equally efficacious. As described above, the majority felt efficacy was 382 
ultimately a matter for the scientists, and none of the participants expressed a strong 383 
preference for a particular dose based on efficacy. A few parents and girls thought that two 384 
or three doses might offer more protection and would be more ‘helpful’ (compared with one 385 











offering a longer period of protection. One parent thought that three doses were each a 387 
third as ‘strong’ as one dose, and another expressed concern therefore that one dose might 388 
be ‘too much medicine’ in one go (mother age 50-55 years; 3 dose arm). 389 
 390 
 One parent whose daughter received two doses said she wished ‘that if there is a possibility 391 
of adding some more, then give her that remaining one so that she can finish’ (Father aged 392 
45-50 years; 2 dose arm), implying a belief that a girl receiving less than three doses had 393 
not received the full course.  Belief that three doses offered more protection was also 394 
implied in the view that if a girl is sexually active, she may require more doses:  395 
 “Because I see [HPV] is a result of sex. It means if she likes [sex] so much, it's better to 396 
receive two vaccines” (Mother aged 40-45 years; 1 dose arm).  397 
 398 
 Of girls expressing an opinion on efficacy, several thought that the doses were equivalent:  399 
 “that one dose is as powerful as the other doses”. (Girl aged 14 years: 1 dose).  400 
  401 
 Only a few girls said they thought that two/three doses might be more efficacious than one 402 
dose.  These girls tended to view two and three doses as equally effective and generally 403 
said that they would prefer two doses because it implied one less injection.  404 
 405 
4. DISCUSSION 406 
  407 
 This study explored whether dosage mattered to girls, and parents/guardians of girls, who 408 
had enrolled in an HPV vaccine dose reduction trial and completed all of their scheduled 409 
doses. We found that being randomly allocated to the number of doses did not feature 410 
highly in their decision to participate. Instead participants thought primarily about the 411 











effectiveness of the vaccine. Girls were particularly concerned about the pain of injection. In 413 
the context of the trial, decisions about dosage were viewed as outside of participant 414 
expertise and therefore not their concern.  Entrusting this to experts reflected, to some 415 
extent, the polarised context in which the decision to participate in the trial was enacted. 416 
Where the decision to participate was was often taken in the context of opposition and 417 
rumour-mongering in the community, it was perceived as courageous. Given a hypothetical 418 
choice, girls generally said that they would prefer fewer doses in order to avoid the pain of 419 
injections. Views among parents were mixed, with most wanting whichever dose was most 420 
efficacious. Nonetheless, a few parents equated a higher number of doses with greater 421 
protection, believing that the vaccine would stay longer in the body or that three injections 422 
implied the full course. In the context of a trial, three doses was also perceived as implying  423 
more medical attention to an enrolled daughter.  424 
 425 
 This study is rare in its explicit focus on dosage in relation to HPV vaccine acceptability and 426 
in directly seeking the views of girls as well as their parents. It contributes to a sparse 427 
literature on actual HPV vaccine acceptability in low-income settings. The main limitation is 428 
that the sample comprises only girls, and/or parents/guardians of girls, who agreed to 429 
participation in a vaccine trial and who completed their clinic visit scheduled for six months 430 
after the first vaccine dose. Although we originally planned to interview girls, and parents of 431 
girls, who did not complete their vaccine course, no girls met the study protocol criteria for 432 
non-completion of the vaccine schedule (i.e. missing one or more vaccine doses) but 433 
remaining in the study. Five girls (0.5%) missed one or two vaccine doses but left the study 434 
(e.g. due to relocation); two girls (0.2%) missed their month 6 visit but were in the single 435 
dose arm and so did not miss a dose. The absence of non-completion in itself provides 436 
further support for the qualitative evidence suggesting that dosage randomisation did not 437 











However, we do not know whether other families or girls declined participation because of 439 
concerns related to vaccine dosage. The active community liaison system for the trial had 440 
not detected any negative rumours related to vaccine dosage at the completion of the 441 
acceptability study, but it is possible that we missed rumours circulating among the wider 442 
community.  It is also worth noting that the DoRIS trial did not have a placebo control arm 443 
and this may have led to enrolment of a group more positively disposed to the HPV vaccine 444 
(since getting the vaccine was certain).  Some of the positivity towards the HPV vaccine 445 
may have reflected an element of resoluteness in the context of perceived opposition from 446 
neighbours. Compared with the rumours around vaccine safety, uncertainty around dosage 447 
may have appeared a risk of much lower magnitude. It is difficult to determine whether, 448 
outside of a trial context, dosage would remain of small significance. 449 
 450 
 In terms of the qualitative design, we opted to include paired interviews because we were 451 
interested in whether the dynamic between parent/guardian and child could provide insight 452 
into decision making processes. What we actually found was that daughter participants 453 
tended to say less and defer to their parent/guardian, such that these interviews were less 454 
good at drawing out daughter views. Finally, in common with all qualitative research, the 455 
study provides a nuanced account of the range of views and experiences, but cannot 456 
comment on their frequency or associations with other factors of interest.   457 
 458 
 The girls and parents interviewed in this study often struggled with the concept of 459 
randomisation by dosage. Difficulty understanding the concept of randomisation has also 460 
been identified among adolescents (16-19 years) in the context of HIV vaccine trials in high-461 
income country settings [20], [21]. Communicating risk is complicated [22]; key questions 462 
regard the right level of information, how to couch uncertainty and the risk of introducing 463 











vaccine trials, it is suggested that limited knowledge can elevate concerns among 465 
participants [23], [24], [25] [26]. However, retention in the DoRIS trial has been very high 466 
with retention, with >95% attending their clinic visit scheduled for 24 months after the first 467 
vaccine dose. This suggests that participants do value their ongoing participation in the trial. 468 
 469 
 We found a tendency among a few parents/guardians to equate a higher number of doses 470 
with greater protection. Any national vaccination programme switching to a lower dose will 471 
need to consider how to address this belief.  Since fewer doses are also recognised to be 472 
cheaper, there may also be suspicion that a switch to fewer doses is driven by a desire (by 473 
government or vaccinators) to cut costs. These views may be counterbalanced by the 474 
greater convenience (and in some cases cost-saving) to participants of a single dose, and 475 
for girls, the benefit of fewer injections. Any education strategies designed to manage a 476 
switch to a lower dose regimen could incorporate these findings into their messaging. 477 
Vaccination programmes over many decades have shown that strategies beyond 478 
information-giving are also required to support and facilitate implicit trust in the science of 479 
vaccination [27].  Strategies such as community engagement are essential but cannot 480 
necessarily prevent opposition and there is tension between recruiting sufficient numbers 481 
for trials and empowering communities to potentially say ‘no’ to participation [28]. 482 
 483 
5. CONCLUSIONS 484 
 485 
A switch to a single-dose vaccine will alleviate some but not all of the barriers to vaccine 486 
coverage. In settings where the vaccine is administered in primary care, it will remove the 487 
need for additional visits [29] and the risk that subsequent doses will be forgotten [30].  It 488 
will also significantly reduce overall delivery costs and may make it easier to integrate a 489 











participants suggests that switching to a single-dose vaccine would not pose major 491 
acceptability issues among those pre-disposed to vaccine uptake. Given the 492 
misunderstandings highlighted in our study, vaccine trials and programmes will need to 493 
employ careful messaging to highlight the benefits of a single dose and to explain that one 494 
dose offers sufficient protection against HPV. 495 
 496 
In addition, other system-level barriers common to many resource-poor settings  - 497 
inadequate infrastructure, limited heath professional training, lack of means to pay, lack of a 498 
regular health care provider, inconsistent endorsement of vaccine by health care providers, 499 
little contact with medical system; low school attendance [31], [32] - will still need to be 500 
tackled and efforts to address them maintained. Since completion of this study, global 501 
vaccination efforts to combat the spread of Cov-Sars-2 have drawn renewed attention to 502 
vaccine hesitancy and barriers to implementation of programmes, and will undoubtedly 503 
have a bearing on how these challenges are tackled in future.  504 
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Table 1: Key characteristics of interview sample 
 
 GIRLS (n = 19) PARENTS (n = 18) 





























































Occupation of parent1 
Vendor, salesman/woman 
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Number of doses
The fact that the vaccine protects against an STI
Side-effects of vaccine such as pain, fever
Risks of vaccination
Age of girl/daughter
 Effectiveness of the vaccine
Risk of cervical cancer if not vaccinated.
Severity of cervical cancer
Figure one. Card exercise results: Extent to which factors were 
considered in decision to participate in trial  








Does the number of doses matter? A qualitative study of HPV vaccination 




 We interviewed girls and parents/carers, of girls, enrolled in an HPV Vaccine dose 
reduction trial  
 We found that enrolling in the trial in the context of community wariness/rumours 
required courage and trust in the trial scientists 
 Scientists were trusted to decide on dosage; thus randomisation by dosage was not an 
acceptability issue 
 Girls preferred fewer vaccine doses in order to avoid injection-related pain 
 Parents/carers generally wanted whichever dose was most efficacious; only a few 
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